GSK Bringing $2.6B Takeover Bid To Human Genome Investors
GlaxoSmithKline PLC will sidestep a requested review from takeover target Human Genome Science Inc. and instead put its unsolicited $2.59 billion bid directly up to a Human Genome shareholder vote, GSK...To view the full article, register now.
Already a subscriber? Click here to view full article